Creative Commons source reading · Clinical neurodiagnostics
Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.
Åsa Sandelius; Henrik Zetterberg; Kaj Blennow; Rocco Adiutori; Andrea Malaspina; Matilde Laura; Mary M Reilly; Alexander M Rossor
Originally published in Neurology · 2018-01-10
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Objective To perform a cross-sectional study to determine whether plasma neurofilament light chain (NfL) concentration is elevated in patients with Charcot-Marie-Tooth disease (CMT) and if it correlates with disease severity. Methods Blood samples were collected from 75 patients with CMT and 67 age-matched healthy controls over a 1-year period. Disease severity was measured using the Rasch modified CMT Examination and neuropathy scores. Plasma NfL concentration was measured using an in-house-developed Simoa assay. Results Plasma NfL concentration was significantly higher in patients with CMT (median 26.0 pg/mL) compared to healthy controls (median 14.6 pg/mL, p r = 0.43, p r = 0.37, p = 0.044) scores. Concentrations were also significantly higher when subdividing patients by genetic subtype ( CMT1A , SPTLC1 , and GJB1 ) or into demyelinating or axonal forms compared to healthy controls. Conclusion There are currently no validated blood biomarkers for peripheral neuropathy.
Discussion
In this study, we have demonstrated that plasma NfL concentration is increased in patients with inherited peripheral neuropathy and that it correlates with disease severity. It is important to emphasize that raised plasma NfL concentration was not limited to CMT1A, but was significantly elevated in the 2 other forms of CMT with sufficient numbers of participants for analysis (CMT1X and HSN1). This suggests a role for plasma NfL in monitoring disease activity may be extended to multiple forms of CMT.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
